Induction of apoptosis through targeting Bcl-2 anti-apoptotic proteins is an effective therapeutic strategy for hematologic malignancies, and Bcl-2 inhibitor venetoclax is widely used to treat AML and CLL (Ramsey et al. 2018). Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.